BLGO Stock Overview
BioLargo, Inc. invents, develops, and commercializes various platform technologies.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.17|
|52 Week High||US$0.29|
|52 Week Low||US$0.15|
|1 Month Change||-23.47%|
|3 Month Change||-33.51%|
|1 Year Change||-10.31%|
|3 Year Change||-0.17%|
|5 Year Change||-64.13%|
|Change since IPO||-75.40%|
Recent News & Updates
|BLGO||US Chemicals||US Market|
Return vs Industry: BLGO underperformed the US Chemicals industry which returned -6.2% over the past year.
Return vs Market: BLGO matched the US Market which returned -10.4% over the past year.
|BLGO Average Weekly Movement||8.7%|
|Chemicals Industry Average Movement||7.1%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BLGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BLGO's weekly volatility (9%) has been stable over the past year.
About the Company
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company’s technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services.
BioLargo Fundamentals Summary
|BLGO fundamental statistics|
Is BLGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLGO income statement (TTM)|
|Cost of Revenue||US$1.43m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.026|
|Net Profit Margin||-279.73%|
How did BLGO perform over the long term?See historical performance and comparison
Is BioLargo undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLGO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BLGO's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BLGO is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: BLGO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLGO is overvalued based on its PB Ratio (9.9x) compared to the US Chemicals industry average (2.1x).
How is BioLargo forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioLargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has BioLargo performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLGO is currently unprofitable.
Growing Profit Margin: BLGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLGO is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare BLGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLGO is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (34.5%).
Return on Equity
High ROE: BLGO has a negative Return on Equity (-738.91%), as it is currently unprofitable.
How is BioLargo's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BLGO's short term assets ($1.8M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: BLGO's short term assets ($1.8M) exceed its long term liabilities ($716.0K).
Debt to Equity History and Analysis
Debt Level: BLGO has more cash than its total debt.
Reducing Debt: BLGO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLGO has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BLGO is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
What is BioLargo current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLGO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BLGO has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dennis Calvert (58 yo)
Mr. Dennis P. Calvert serves as the Chairman of the Board at BioLargo, Inc. and has been its Chief Executive Officer and President since June 28, 2002. Mr. Calvert has an extensive entrepreneurial backgrou...
CEO Compensation Analysis
Compensation vs Market: Dennis's total compensation ($USD651.45K) is about average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Dennis's compensation has been consistent with company performance over the past year.
Experienced Management: BLGO's management team is seasoned and experienced (19.2 years average tenure).
Experienced Board: BLGO's board of directors are seasoned and experienced ( 15.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.
BioLargo, Inc.'s employee growth, exchange listings and data sources
- Name: BioLargo, Inc.
- Ticker: BLGO
- Exchange: OTCPK
- Founded: 1991
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: US$46.022m
- Shares outstanding: 267.26m
- Website: https://www.biolargo.com
Number of Employees
- BioLargo, Inc.
- 14921 Chestnut Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.